Vimarsana
Biggest News Aggregation in the World

Page 28 - Genentech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genentech Today - Breaking & Trending Today

25 Richest Billionaires in Healthcare Industry - Vimarsana News

25 Richest Billionaires in Healthcare Industry

In this article, we discuss the 25 richest billionaires in healthcare industry.

Mind, Body, and Spiritual Well-Being for Women Addressed in NAACP Forum in Oakland | - Vimarsana News

Mind, Body, and Spiritual Well-Being for Women Addressed in NAACP Forum in Oakland |

The Women In The NAACP Oakland Branch is proud to announce the upcoming “Total You - Mind, Body, and Spirit Women's Health Forum” scheduled for April 27 at Acts Full Gospel Church. Running from 9 a.m.-2 p.m. at 1034 66th Ave., this forum aims to provide an empowering platform for women to engage in discussions, gain knowledge, and access resources pertaining to their health and well-being. | Special to The Post The Women In The NAACP Oakland Branch is proud to announce the upcoming “Total You - Mind, Body, and Spirit Women's Health Forum” scheduled for April 27 at Acts Full G...

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - Vimarsana News

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

Hong Kong's R&D Receives International Recognition HKPC's "InspecSpider" Wins Prestigious "Edison Award" in Innovation Field - Vimarsana News

Hong Kong's R&D Receives International Recognition HKPC's "InspecSpider" Wins Prestigious "Edison Award" in Innovation Field

LiveNews Provides news reports of information as it happens in real time of politics, business, the economy and also reports on global issues and events from a New Zealand viewpoint.

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC - Vimarsana News

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy